奥美沙坦酯的早期降压疗效。
Early antihypertensive efficacy of olmesartan medoxomil.
作者信息
Saito Ikuo, Kushiro Toshio, Ishikawa Mayumi, Matsushita Yasuyuki, Sagawa Kei, Hiramatsu Katsutoshi, Komiya Masahiro
机构信息
Keio University Health Center, Tokyo, Japan.
出版信息
J Clin Hypertens (Greenwich). 2008 Dec;10(12):930-5. doi: 10.1111/j.1751-7176.2008.00050.x.
The authors assessed the early antihypertensive efficacy of olmesartan medoxomil (OM) in a 12-week prospective observational study. Of 2221 patients with untreated hypertension who received OM (mainly 10 or 20 mg), 331 patients whose blood pressure (BP) was measured at 1 week after initiation of treatment were defined as the "early BP determination group,'' whereas the remaining 1890 patients were defined as the ;;standard BP determination group.'' Baseline characteristics, doses of OM, concomitant drugs used, and BP during treatment did not differ between the 2 groups. The achievement rate of BP target (<140/90 mm Hg) was 28.4% at 1 week in the early BP determination group and 28.3% at 2 weeks in the standard BP determination group (P=NS). Rates of adverse drug reactions in the 2 groups were similar. The present study suggests that OM is safe and effective in reducing BP at an early time point of treatment.
作者在一项为期12周的前瞻性观察研究中评估了奥美沙坦酯（OM）的早期降压疗效。在2221例接受OM治疗（主要为10或20mg）的未经治疗的高血压患者中，331例在开始治疗1周后测量血压的患者被定义为“早期血压测定组”，而其余1890例患者被定义为“标准血压测定组”。两组之间的基线特征、OM剂量、使用的伴随药物以及治疗期间的血压无差异。早期血压测定组在1周时血压目标（<140/90mmHg）达成率为28.4%，标准血压测定组在2周时为28.3%（P=无显著性差异）。两组药物不良反应发生率相似。本研究表明，OM在治疗早期降低血压方面安全有效。
Zotero 插件